Pharmacy World and Science

, Volume 21, Issue 5, pp 239–240 | Cite as

Pilot study in humans on the pharmacokinetics and safety of propofol 6% SAZN

  • Catherijne A.J. Knibbe
  • Victorine S. Koster
  • Leon P.H.J. Aarts
  • Han J.M. Langemeijer
  • Meindert Danhof


In a pilot study on the first application of Propofol 6% SAZN in humans, the pharmacokinetics and safety of the new product seem to be similar to those of Propofol 1% SAZN and Diprivan®‐10 after bolus injection. The results will have to be confirmed in a larger clinical study in order to develop Propofol 6% SAZN as an alternative for Diprivan®‐10.

anaesthesia Clinical pharmacology Emulsion formulation Fat emulsion Propofol Pharmacokinetics 


  1. 1.
    Bryson HM, Fulton BR, Faulds D. Propofol. An update of its use in anaesthesia and conscious sedation. Drugs 1995;50:513-59.PubMedGoogle Scholar
  2. 2.
    Fulton B, Sorkin EM. Propofol. An overview of its pharmacology and a review of its clinical efficacy in intensive care sedation. Drugs 1995;50:636-57.PubMedGoogle Scholar
  3. 3.
    Gottardis M, Khünl-Brady KS, Koller W, Sigl G, Hackl JM. Effect of prolonged sedation with propofol on serum triglyceride and cholesterol concentrations. Br J Anaesth 1989;62:393-6.PubMedGoogle Scholar
  4. 4.
    Parke TJ, Stevens JE, Rice ASC, et al. Metabolic acidosis and fatal myocardial failure after propofol infusion in children: five case reports. BMJ 1992;305:613-6.PubMedGoogle Scholar
  5. 5.
    Knibbe CAJ, Koster VS, Deneer VHM, Stuurman RM, Kuks PFM, Lange R. Determination of propofol in low volume samples by high-performance liquid chromatography with fluorescence detection. J Chromatogr B Biomed Sci Appl 1998;706:305-10.PubMedGoogle Scholar
  6. 6.
    Cummings GC, Dixon J, Kay NH, et al. Dose requirements of ICI 35,868 (Propofol, 'Diprivan') in a new formulation for induction of anaesthesia. Anaesthesia 1984;39:1168-71.PubMedGoogle Scholar
  7. 7.
    Dutta S, Matsumoto Y, Ebling WF. Propofol pharmacokinetics and pharmacodynamics assessed from a cremophor EL formulation. J Pharm Sci 1997;86:967-9.PubMedGoogle Scholar
  8. 8.
    Dutta S, Ebling WF. Emulsion formulation reduces propofol dose requirements and enhances safety. Anesthesiology 1997;87:1394-405.PubMedGoogle Scholar
  9. 9.
    Doenicke AW, Roizen MF, Rau J, et al. Pharmacokinetics and pharmacodynamics of propofol in a new solvent. Anesth Analg 1997;85:1399-403.PubMedGoogle Scholar
  10. 10.
    Cox EH, Knibbe CAJ, Koster VS, et al. Influence of different fat emulsion-based intravenous formulations on the pharmacokinetics and pharmacodynamics of propofol. Pharm Res 1998;15:442-8.PubMedGoogle Scholar

Copyright information

© Kluwer Academic Publishers 1999

Authors and Affiliations

  • Catherijne A.J. Knibbe
  • Victorine S. Koster
  • Leon P.H.J. Aarts
  • Han J.M. Langemeijer
  • Meindert Danhof

There are no affiliations available

Personalised recommendations